JP2001502671A - HMG―CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物 - Google Patents
HMG―CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物Info
- Publication number
- JP2001502671A JP2001502671A JP10517440A JP51744098A JP2001502671A JP 2001502671 A JP2001502671 A JP 2001502671A JP 10517440 A JP10517440 A JP 10517440A JP 51744098 A JP51744098 A JP 51744098A JP 2001502671 A JP2001502671 A JP 2001502671A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fluvastatin
- release
- formulation
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.活性成分としてフルバスタチンの水溶性塩を含有しており、そして基質処方 物、拡散制御膜被覆処方物;及びそれらの組合せからなる群より選ばれる徐放性 医薬組成物。 2.前記フルバスタチンの水溶性塩がナトリウム塩である請求項1に記載の医薬 組成物。 3.浸食性基質処方物である請求項1又は2に記載の医薬組成物。 4.基質物質がポリエチレンオキシド、ヒドロキシプロピルメチルセルロース及 びパラフィンからなる群より選ばれる請求項3に記載の医薬組成物。 5.非浸食性基質処方物である請求項1又は2に記載の医薬組成物。 6.基質物質がキサンタン及びポリ塩化ビニルからなる群より選ばれる請求項5 に記載の医薬組成物。 7.拡散制御膜被覆処方物である請求項1又は2に記載の医薬組成物。 8.膜形成用物質がエチルセルロース、ヒドロキシプロプルメチルセルロース及 びヒドロキシプロピルセルロースからなる群より選ばれる請求項7に記載の医薬 組成物。 9.高コレステロール血症の治療に使用するための請求項1〜8のいずれか一項 に記載の医薬組成物。 10.高コレステロール血症の治療用徐放性医薬組成物の製造のためのフルバスタ チンの水溶性塩の使用。 11.前記医薬組成物が基質処方物、拡散制御膜被覆処方物;及びそれらの組合せ からなる群より選ばれる請求項10に記載の使用。 12.人を含む哺乳動物にフルバスタチンの水溶性塩を含有する徐放性医薬組成物 の治療上有効な量を投与することからなる高コレステロール血症 の治療方法。 13.前記医薬組成物が基質処方物、拡散制御膜被覆処方物;及びそれらの組合せ からなる群より選ばれる請求項12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9603667-8 | 1996-10-08 | ||
SE9603667A SE9603667D0 (sv) | 1996-10-08 | 1996-10-08 | Pharmaceutical compositions |
PCT/SE1997/001604 WO1998015264A1 (en) | 1996-10-08 | 1997-09-24 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008308734A Division JP2009102339A (ja) | 1996-10-08 | 2008-12-03 | HMG−CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001502671A true JP2001502671A (ja) | 2001-02-27 |
JP2001502671A5 JP2001502671A5 (ja) | 2005-05-12 |
JP4627810B2 JP4627810B2 (ja) | 2011-02-09 |
Family
ID=20404165
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51744098A Expired - Lifetime JP4627810B2 (ja) | 1996-10-08 | 1997-09-24 | HMG―CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物 |
JP2008308734A Pending JP2009102339A (ja) | 1996-10-08 | 2008-12-03 | HMG−CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008308734A Pending JP2009102339A (ja) | 1996-10-08 | 2008-12-03 | HMG−CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物 |
Country Status (13)
Country | Link |
---|---|
US (5) | US20030194440A1 (ja) |
EP (1) | EP0948320B1 (ja) |
JP (2) | JP4627810B2 (ja) |
AT (1) | ATE236619T1 (ja) |
AU (1) | AU4578097A (ja) |
CY (1) | CY2469B1 (ja) |
DE (1) | DE69720778T2 (ja) |
DK (1) | DK0948320T3 (ja) |
ES (1) | ES2197369T3 (ja) |
PT (1) | PT948320E (ja) |
SE (1) | SE9603667D0 (ja) |
SI (1) | SI0948320T1 (ja) |
WO (1) | WO1998015264A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199878A (ja) * | 1999-09-13 | 2001-07-24 | Lab Del Dr Esteve Sa | 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤 |
JP2005538097A (ja) * | 2002-07-25 | 2005-12-15 | ノバルティス アクチエンゲゼルシャフト | Hmg−coaレダクターゼインヒビターを含む組成物 |
JP2006298945A (ja) * | 1998-10-14 | 2006-11-02 | Novartis Ag | 徐放性医薬組成物および薬学的活性剤の放出の方法 |
JP2009527577A (ja) * | 2006-02-24 | 2009-07-30 | テバ ファーマシューティカル インダストリーズ リミティド | フルバスタチンナトリウム医薬組成物 |
WO2013031729A1 (ja) | 2011-08-26 | 2013-03-07 | 国立大学法人大阪大学 | 糖尿病性心血管合併症の予防・治療剤 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5758799A (en) * | 1998-09-25 | 2000-04-17 | Sankyo Company Limited | Hmg-coa reductase inhibitor-containing preparations |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
DE19954421A1 (de) | 1999-11-12 | 2001-05-31 | Lohmann Therapie Syst Lts | Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
SI21400A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska družba d.d. | Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze |
UA85717C2 (uk) * | 2004-05-24 | 2009-02-25 | Нікомед Фарма Ас | Сипкий матеріал, який містить кальцієвмісну сполуку і цукровий спирт |
WO2006082523A2 (en) * | 2005-01-25 | 2006-08-10 | Aurobindo Pharma Limited | Pharmaceutical sustained release composition of metformin |
US20060229277A1 (en) * | 2005-04-08 | 2006-10-12 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
EP1825848A3 (de) * | 2006-02-10 | 2010-03-03 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
EP1818050A1 (de) * | 2006-02-10 | 2007-08-15 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
EP1928425B1 (en) * | 2006-05-12 | 2013-01-23 | Pharmathen S.A. | Pharmaceutical formulation containing fluvastatin |
EP1911441A3 (en) * | 2006-10-11 | 2008-08-06 | Lupin Limited | Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents |
WO2008064259A2 (en) * | 2006-11-21 | 2008-05-29 | Biokey, Inc. | Solid dispersion composition comprising fluvastatin |
IS8612A (is) * | 2007-02-19 | 2008-08-20 | Actavis Group Ptc Ehf. | Stöðugar statínlyfjasamsetningar |
US8530528B2 (en) * | 2010-02-01 | 2013-09-10 | Clariant Corporation | Water-forming hydrogenation reactions utilizing enhanced catalyst supports and methods of use |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
CN102755284B (zh) * | 2011-12-22 | 2014-11-05 | 深圳信立泰药业股份有限公司 | 一种氟伐他汀缓释药物组合物 |
EP3003297A4 (en) | 2013-06-05 | 2017-04-19 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6319152A (ja) * | 1986-06-16 | 1988-01-26 | ジヨンソン・アンド・ジヨンソン・プロダクツ・インコ−ポレイテツド | 薬物放出制御薬用薄膜及びその製造方法 |
JPH02237937A (ja) * | 1988-11-21 | 1990-09-20 | Merck & Co Inc | 有意に低減した量の酵素阻害剤を循環血流中に連続供給する薬剤供給装置 |
JPH05246844A (ja) * | 1991-12-12 | 1993-09-24 | Sandoz Ag | HMG−CoAリダクターゼ禁止剤化合物を含んでなる安定化された製薬学的組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3965255A (en) * | 1974-05-01 | 1976-06-22 | E. E. Eljim Ecology Ltd. | Controlled drug releasing preparations |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
GB8521494D0 (en) * | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
US5238686A (en) * | 1986-03-27 | 1993-08-24 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
JP2681373B2 (ja) * | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | 徐放性製剤の製造法 |
US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
CA2045428A1 (en) * | 1990-06-26 | 1991-12-27 | Alfred W. Alberts | Method for enhancing the lowering of plasma cholesterol levels |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
US5273758A (en) * | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
JP3130674B2 (ja) * | 1992-04-10 | 2001-01-31 | 富士写真フイルム株式会社 | 磁気記録媒体 |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5395626A (en) * | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
JP2849047B2 (ja) * | 1994-12-19 | 1999-01-20 | 大正薬品工業株式会社 | ジクロフェナクナトリウム持続性製剤およびその製法 |
US5534263A (en) * | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
-
1996
- 1996-10-08 SE SE9603667A patent/SE9603667D0/xx unknown
-
1997
- 1997-09-24 EP EP97944240A patent/EP0948320B1/en not_active Revoked
- 1997-09-24 DE DE69720778T patent/DE69720778T2/de not_active Expired - Lifetime
- 1997-09-24 WO PCT/SE1997/001604 patent/WO1998015264A1/en active IP Right Grant
- 1997-09-24 US US08/945,655 patent/US20030194440A1/en not_active Abandoned
- 1997-09-24 DK DK97944240T patent/DK0948320T3/da active
- 1997-09-24 ES ES97944240T patent/ES2197369T3/es not_active Expired - Lifetime
- 1997-09-24 SI SI9730548T patent/SI0948320T1/xx unknown
- 1997-09-24 JP JP51744098A patent/JP4627810B2/ja not_active Expired - Lifetime
- 1997-09-24 PT PT97944240T patent/PT948320E/pt unknown
- 1997-09-24 AT AT97944240T patent/ATE236619T1/de active
- 1997-09-24 AU AU45780/97A patent/AU4578097A/en not_active Abandoned
-
2003
- 2003-12-17 US US10/738,196 patent/US20040132814A1/en not_active Abandoned
-
2004
- 2004-08-10 CY CY0400060A patent/CY2469B1/xx unknown
-
2006
- 2006-10-10 US US11/545,650 patent/US20070031493A1/en not_active Abandoned
-
2008
- 2008-12-03 JP JP2008308734A patent/JP2009102339A/ja active Pending
-
2010
- 2010-06-08 US US12/795,801 patent/US20100291217A1/en not_active Abandoned
- 2010-06-08 US US12/795,774 patent/US20100291216A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6319152A (ja) * | 1986-06-16 | 1988-01-26 | ジヨンソン・アンド・ジヨンソン・プロダクツ・インコ−ポレイテツド | 薬物放出制御薬用薄膜及びその製造方法 |
JPH02237937A (ja) * | 1988-11-21 | 1990-09-20 | Merck & Co Inc | 有意に低減した量の酵素阻害剤を循環血流中に連続供給する薬剤供給装置 |
JPH05246844A (ja) * | 1991-12-12 | 1993-09-24 | Sandoz Ag | HMG−CoAリダクターゼ禁止剤化合物を含んでなる安定化された製薬学的組成物 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006298945A (ja) * | 1998-10-14 | 2006-11-02 | Novartis Ag | 徐放性医薬組成物および薬学的活性剤の放出の方法 |
JP2001199878A (ja) * | 1999-09-13 | 2001-07-24 | Lab Del Dr Esteve Sa | 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤 |
JP2005538097A (ja) * | 2002-07-25 | 2005-12-15 | ノバルティス アクチエンゲゼルシャフト | Hmg−coaレダクターゼインヒビターを含む組成物 |
JP2009527577A (ja) * | 2006-02-24 | 2009-07-30 | テバ ファーマシューティカル インダストリーズ リミティド | フルバスタチンナトリウム医薬組成物 |
WO2013031729A1 (ja) | 2011-08-26 | 2013-03-07 | 国立大学法人大阪大学 | 糖尿病性心血管合併症の予防・治療剤 |
US9393224B2 (en) | 2011-08-26 | 2016-07-19 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
Also Published As
Publication number | Publication date |
---|---|
SI0948320T1 (en) | 2003-10-31 |
US20030194440A1 (en) | 2003-10-16 |
WO1998015264A1 (en) | 1998-04-16 |
DK0948320T3 (da) | 2003-08-04 |
ES2197369T3 (es) | 2004-01-01 |
ATE236619T1 (de) | 2003-04-15 |
US20100291216A1 (en) | 2010-11-18 |
US20100291217A1 (en) | 2010-11-18 |
JP4627810B2 (ja) | 2011-02-09 |
JP2009102339A (ja) | 2009-05-14 |
AU4578097A (en) | 1998-05-05 |
US20040132814A1 (en) | 2004-07-08 |
US20070031493A1 (en) | 2007-02-08 |
DE69720778T2 (de) | 2004-02-05 |
CY2469B1 (en) | 2005-06-03 |
DE69720778D1 (de) | 2003-05-15 |
EP0948320A1 (en) | 1999-10-13 |
SE9603667D0 (sv) | 1996-10-08 |
EP0948320B1 (en) | 2003-04-09 |
PT948320E (pt) | 2003-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4627810B2 (ja) | HMG―CoA還元酵素阻害剤フルバスタチンの徐放性医薬組成物 | |
RU2179017C2 (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ (варианты) и способ ее получения (варианты) | |
JP4758064B2 (ja) | 有効物質を徐放する3−(3−ジメチルアミノ−1−エチル−2−メチル−プロピル)フェノール含有医薬 | |
TWI241188B (en) | Sertraline salts and sustained-release dosage forms of sertraline | |
JP2004501190A (ja) | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 | |
JP2003503341A (ja) | 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態 | |
EP4249055A2 (en) | Tofacitinib oral sustained release dosage forms | |
JP2009502987A (ja) | カルビドパとレボドパを含有する延長放出型固形医薬組成物 | |
JP2008540437A (ja) | キニーネを含有する制御放出調合剤 | |
KR20080007252A (ko) | 양성 전립선 과다형성증용 치료 조합물 | |
WO1998027967A1 (en) | Release-controlled coated tablets | |
JP2006528237A (ja) | バレニクリンの医薬組成物 | |
JP2003502360A (ja) | トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形 | |
JPH01313427A (ja) | ジヒドロピリジン類を含有する徐放性製剤 | |
JP2005526739A (ja) | コレステロール濃度を低下させる活性成分を含み、活性成分が遅延放出される薬剤 | |
AU684786B2 (en) | A drug delivery composition for alpha-adreno receptor blocking agents | |
EP4069207A1 (en) | Modified release pharmaceutical compositions of riociguat | |
WO2004024128A2 (en) | Modified release ketoprofen dosage form | |
WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
RU2411035C2 (ru) | Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината | |
JP2005510477A (ja) | 抗痙攣薬の間隙をあけたドラッグデリバリーシステム | |
JP4696210B2 (ja) | イソソルビド‐5‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法 | |
WO2008062426A2 (en) | Formulation of benzazepine derivatives | |
WO2007010508A2 (en) | Controlled release compositions of metaxalone | |
JP2003146882A (ja) | 生理活性物質含有固形物の溶出速度を制御する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040921 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080903 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081001 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101102 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101109 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131119 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |